Fueling Life
Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing first-in-class drug candidates. Our lead product candidate, trans sodium crocetinate (TSC), is a synthetic small-molecule that uses a novel method of action to enhance oxygen diffusion to oxygen-deprived (hypoxic) tissue. We believe that TSC has the potential to treat millions of patients annually for conditions in which hypoxia is present, including cardiovascular and respiratory diseases, stroke, cancer and other serious conditions with unmet medical needs.
A Phase I study of TSC in healthy subjects was successfully completed in 2007. In September 2008, the company initiated a Phase I/II proof-of-concept and dose-finding study in peripheral arterial disease patients suffering from intermittent claudication. Study completion and data unblinding are scheduled for late 2009. The annual market for a new peripheral arterial disease treatment is estimated at over a billion dollars in the United States alone.
Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia.
February 25, 2009
Diffusion Pharmaceuticals Featured in NPR Story on New Stroke Treatment
Scientists in Charlottesville are studying what could be a whole new approach to treating stroke—the nation’s leading cause of disability and the third leading cause of death. WVTF’s Sandy Hausman reports on the research.
Listen
Dr. Lee is chair of the Department of Neuroscience at the University of Virginia School of Medicine, and will present […]
February 6, 2009
Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
CHARLOTTESVILLE, VA – February 6, 2009 – Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs that enhance oxygen diffusion, today announced the completion of a $2.9 million private placement. The proceeds will support the company’s overall growth and clinical programs for its lead drug compound, trans sodium crocetinate (TSC). […]
September 2, 2008
Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
September is National Vascular Disease Awareness Month
CHARLOTTESVILLE, VA – September 3, 2008 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC). […]
